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Summary The effect of clodronate on bone mineral density (BMD) was studied in 121 post-menopausal breast cancer women without
skeletal metastases. In addition, two antioestrogens, tamoxifen and toremifene, were compared in their action on bone mineral density.
Patients were randomized to have an adjuvant antioestrogen treatment either 20 mg of tamoxifen or 60 mg of toremifene daily for 3 years. In
addition all patients were randomized to have 1600 mg of oral clodronate daily or to act as control subjects. BMD of the lumbar spine and
femoral neck were measured by dual-energy radiographic absorptiometry before therapy and at 1 and 2 years. At 2 years, clodronate with
antioestrogens markedly increased BMD in the lumbar spine and femoral neck by 2.9% and 3.7% (P= 0.001 and 0.006 respectively). There
were no significant changes in BMD in the patients given antioestrogens only. No significant differences were found between tamoxifen and
toremifene on bone mineral density. Clodronate with antioestrogens significantly increased bone mass in the lumbar spine and femoral neck.
Both antioestrogens, tamoxifen and toremifene, similarly prevented bone loss in the lumbar spine and femoral neck.
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Adjuvant antioestrogen treatment with tamoxifen significantly
improves the survival of post-menopausal women with primary
breast cancer (EBCTCG, 1992). Tamoxifen has oestrogen
agonistic effects on bone and therefore prevents bone loss in post-
menopausal women (Love et al, 1992; Ward et al, 1993;
Kristensen et al, 1994; Powles et al, 1996). Tamoxifen has been
shown to prevent bone loss predominantly in the lumbar spine
(Love et al, 1992; Kristensen et al, 1994), but in two randomized
studies this was also true for the upper femur (Ward et al, 1993;
Powles et al, 1996).
Toremifene is a close analogue to tamoxifen with demonstrated
efficacy in advanced breast cancer (Valavaara et al, 1988).
Compared with tamoxifen, toremifene is more oestrogen antago-
nistic than agonistic in rat (Di Salle et al, 1990). At present, no
data are available on the effect oftoremifene on bone.
Since bisphosphonates prevent post-menopausal bone loss
(Chesnut 1984; Reginster et al, 1989; Storm et al, 1990; Watts et
al, 1990; Giannini et al, 1993; Harris et al, 1993; Reid et al, 1994;
Filipponi et al, 1995; Liberman et al, 1995) and in advanced breast
cancer reduced the development of new bone metastases (Elomaa
et al, 1983; Martoni et al, 1991; Paterson et al, 1993; Van Holten
Verzantvoort et al, 1993), they are attractive candidates for the
treatment ofpatients with early breast cancer.
We performed a prospective, open, randomized study to deter-
mine the effect of oral clodronate in post-menopausal women
with primary breast cancer treated with adjuvant antioestrogens,
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tamoxifen or toremifene. In addition, tamoxifen and toremifene
were compared in their action on bone mineral density.
MATERIALS AND METHODS
Patients and methods
The study population consisted of 121 early-stage breast cancer
patients, with no haematogenic metastases. Eligible for the trial
were post-menopausal women with operable breast cancer and
histologically proven axillary metastases, TI-3 Nl-2 MO, treated
between May 1992 and July 1993 at Helsinki University Hospital,
Department of Oncology. Exclusion criteria included the
following: (1) age above 75 years; (2) Karnofsky performance
index below 70%; (3) bone metastases within 6 months after BMD
measurement; (4) other malignancies; (5) peptic ulcer or its symp-
toms; and (6) creatinine over 150,mol 1-1. Post-menopausal status
at entry was defined as either no menses for more than 1 year or
shorter duration ofamenorrhoea with follicle-stimulating hormone
(FSH) levels in the post-menopausal range.
All patients underwent surgery with axillary clearance and total
mastectomy or breast-conserving resection. All patients also had
post-operative radiotherapy with megavoltage irradiation (50 Gy
in 25 fractions) to regional lymph nodes and operative scar or
remaining breast after breast-conserving resection, simultaneously
with adjuvant therapy. Patients were randomly allocated to receive
adjuvant antioestrogen therapy: 20 mg of tamoxifen per day or 60
mg of toremifene daily for 3 years. In addition, all patients were
randomized to receive or not to receive 1600 mg oforal clodronate
(Bonefos, Leiras) daily for 3 years.
Informed consent was obtained from all participants. The study
was approved by the local ethics committee at the Department of
Oncology. Helsinki University Hospital. Staging investigations for
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breast cancer included clinical investigation, liver ultrasound,
chest radiograph and bone scintigraphy. Basic laboratory tests
before randomization included a complete blood count and sedi-
mentation rate, liver enzymes (transaminase, alkaline phosphatase
and 5-nucleotidase), serum creatinine, calcium and electrolytes.
Patients were interviewed regarding menopausal status, medica-
tions and other diseases before randomization and every 12
months. Bone scintigraphy and measurements of serum FSH
luteinizing hormone (LH) and oestradiol were performed before
treatment and every 12 months thereafter. Plasma concentrations
of FSH and LH were measured by immunofluorometric assays
(IFMA; Wallac, Turku, Finland) and plasma oestradiol levels were
measured by a radioimmunoassay (RIA; Farmos, Oulunsalo,
Finland). Clinical investigation and basic laboratory safety tests
were repeated every 4 months with a radiological examination if
necessary.
Bone densitometry
Bone mineral density (BMD, g cm-2) was measured by dual-energy
radiographic absorptiometry (DXA) using a Hologic QDR-1000
Table 1 Pretreatment characteristics [mean and (s.d.), median and range, or
absolute number and percentage] of patients in clodronate and control
groups
Clodronate Control
Number of patients 44 49
Age years 61 (7) 62 (7)
Weight (kg) 67 (8) 71 (12)
Height (cm) 163 (6) 163 (5)
Body mass index 25.3 (3.6) 26.7 (4.4)
FSH (U I-') 50.9 3.8-100.1 58.9 14.6-109.0
LH (U 1-) 35.9 2.8-89.2 36.0 10.8-94.5
Oestradiol (nmol l-) 0.02 0.01-0.43 0.02 0.02-0.28
Lumbar spine BMD 0.905 (0.140) 0.952 (0.136)
Femoral neck BMD 0.735 (0.101) 0.774 (0.128)
Karnofsky (%)
100 31 70% 40 82%
90-80 13 30% 9 18%
Operation
Mastectomy 33 75% 33 67%
Lumpectomy 11 25% 16 33%
T
Ti 22 50% 28 57%
T2 15 34% 18 37%
T3 5 11% 2 4%
Unknown 2 5% 1 2%
N
N (1-3) 32 73% 37 76%
N (4-10) 10 23% 10 20%
N (>10) 1 2% 2 4%
1 2% 0
Histology
Ductal 34 77% 43 88%
Lobular 10 23% 5 10%
Other 0 0% 1 2%
Oestrogen receptors
Positive 31 70% 37 76%
Negative 10 23% 8 16%
Unknown 3 7% 4 8%
Progesterone receptors
Positive 22 50% 30 61%
Negative 19 43% 15 31%
Unknown 3 7% 4 8%
densitometer (Hologic Waltham, MA, USA). BMD was measured
at the lumbar vertebrae (LI-L4) and femoral neck in the right
femoral area before the initiation oftherapy and every 12 months.
The coefficient ofvariation forthe precision ofthe BMD measure-
ments in the lumbar vertebrae and femoral neck was 0.9% and
1.2% respectively.
Statistical methods
BMD values are expressed as a percentage of the baseline value.
The effect of treatments (clodronate and antioestrogens) on
changes in BMD at 1 and 2 years was tested by a repeated
measures ANOVA model using the BMDP2V programs (BMDP
Release 7), with change from baseline BMD as the dependent vari-
able, antioestrogen treatment and clodronate treatment as the
grouping variables. Other comparisons were made using the
Mann-Whitney test or Wilcoxon matched pair test. Confidence
intervals (95%) were calculated for the main outcome measures.
RESULTS
Pretreatmentcharacteristics ofthe subjects in the two study groups
are given in Table 1. The two groups were well balanced with
respect to pretreatment characteristics, previous diseases and
medications. There were no severe abnormalities in baseline labo-
ratory tests. None ofthe patients had previously used bisphospho-
nates or calcitonin.
Ofthe 121 eligible patients, data from 28 patients were excluded
from the analyses: 16 owing to metastatic disease, nine as a result
of protocol violation (patients treated with chemotherapy) and
there because of diseases affecting calcium and bone metabolism.
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Figure 1 Changes from baseline and 95% confidence intervals in BMD of
(A) the lumbar spine and (B) femoral neck at 1 and 2 years in the control and
clodronate groups. Clodronate group -_, control group -{-
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Table 2 Percentage changes (mean and 95% confidence intervals) from baseline in BMD of the lumbar spine and femoral neck at 1 and 2 years in the
tamoxifen and toremifene groups
Treatment groups Mean change % (Cl) at 1 year Mean change % (Cl) at 2 years
Control Clodronate Control Clodronate
Lumbarspine
Tamoxifen -0.3 +1.7 -1.5 +2.5
(-1.9 to +1.3) (0 to +3.4) (-3.4 to +0.5) (+0.6 to +4.5)
Toremifene +0.6 +1.1 +0.5 +3.4
(-0.8 to +2.0) (+0.3 to +1.8) (-1.6 to +2.6) (+0.9 to +5.9)
Femoral neck
Tamoxifen +1.0 +3.9 +2.0 +4.2
(-0.9 to +2.9) (+2.2 to +5.6) (-0.6 to +4.5) (+2.2 to +6.1)
Toremifene +0.4 +2.6 -0.3 +3.0
(-2.2 to +3.0) (+0.3 to +4.8) (-3.3 to +1.2) (+0.5 to +5.5)
The number of patients treated with tamoxifen only, toremifene only, tamoxifen with clodronate, and toremifene with clodronate are 23, 21, 23 and 16,
respectively, at both 1 and 2 years.
Thus, 93 patients were eligible for analyses. From the 2 years'
analyses, nine additional patients were excluded: eight because of
breast cancer recurrence and one patients because of discontinua-
tion offollow-up.
Four patients interrupted clodronate treatment: three patients
because of side-effects and one patient because of refusal to
continue therapy. One patient had a dose reduction because of
gastric pain. Five patients interrupted antioestrogen therapy after a
median of 10 months: four because of menopausal symptoms and
one because of increased serum transaminase levels. All these
patients are included in the analyses.
Oral clodronate treatment was well tolerated. Three patients
(3%) interrupted clodronate therapy and one patient reduced the
dose because ofgastric pain. There were no significant differences
in adverse events between the study groups. During the first year
oftherapy, seven patients (8%) reported mild nausea and vomiting,
and three patients (3%) had diarrhoea with no differences between
the study groups. During the second year four (4%) patients
complained about of mild nausea and vomiting, and one patient
had diarrhoea. Renal toxicity was not seen in either group.
Hormonal changes
Antioestrogen therapy decreased FSH and LH levels significantly
in post-menopausal patients: median FSH from 54.6 U 1-' (range
3.8-109) to 29.9 U 1-1 (9.0-66.1), median LH from 36.0 U 1-'
(2.8-94.5) to 20.0 U 1-' (4.4-62.9) (P < 0.0001 and P < 0.0001
respectively, Wilcoxon), with no significant changes in oestradiol
levels. There were no significant differences between the tamox-
ifen and toremifene groups, or between the clodronate and control
groups.
The mean weight gain was 1.4 kg (s.d. 2.8) and 1.4 kg (s.d. 4.5)
at 1 and 2 years of the study (P < 0.0001 and P < 0.0001 respec-
tively, Wilcoxon); there were no significant differences between
the control and clodronate groups, nor between the tamoxifen and
toremifene groups.
Changes in bone mineral density
The baseline values for the BMD of the lumbar spine and the
femoral neck were similar in the clodronate and control groups
(Table 1). In patients receiving clodronate, BMD of the lumbar
spine increased significantly by 1.5% and 2.9% at 1 and 2 years
respectively (within the clodronate group, P = 0.002, and P =
0.002, Wilcoxon), while in the control group BMD of the lumbar
spine was unchanged (between the groups, P = 0.004, ANOVA).
BMD of the femoral neck increased by 3.3% and 3.7% in the
clodronate group at the first and second years (within the
clodronate group, P < 0.0001 and P < 0.0001, Wilcoxon), with no
significant changes in the control group (between the groups, P =
0.003, ANOVA) (Figure 1).
Changes of BMD in the tamoxifen and toremifene groups are
shown in Table 2. The type ofendocrine treatment had no signifi-
cant effect on the BMD of the lumbar spine and femoral neck (at
2 years, P = 0.446 and P = 0.064 respectively).
DISCUSSION
The present study implies that adjuvant antioestrogen treatment
with either tamoxifen or toremifene prevents bone loss in post-
menopausal women. However, bone mineral density can even be
augmented by combining clodronate with the medical treatment of
post-menopausal women with breast cancer.
In line with prior investigations, post-menopausal breast cancer
patients treated with antioestrogens did not lose bone at the lumbar
spine or at the femoral neck (Love et al, 1992; Ward et al, 1993;
Kristensen et al, 1994; Powles et al, 1996). Previous data on
tamoxifen were extended by the finding that a novel antioestrogen,
toremifene, preserved bone mass as effectively as tamoxifen,
although experimental data havo shown it to be less oestrogenic
than tamoxifen (Di Salle etal, 1990). Clodronate provided an addi-
tional benefit for post-menopausal breast cancer patients. In fact,
the clodronate-induced increase in bone mass was quite similar to
that obtained on oestrogen replacement therapy after a natural
menopause (Ettinger et al, 1987, 1992; Genant et al, 1990;
Stevenson et al, 1990).
Our results indicate that clodronate combined with antio-
estrogens augment bone mass in post-menopausal women. A
new antioestrogen, toremifene, had an oestrogen-like effect on
bone similar to tamoxifen. Since clodronate can also inhibit the
development of bone metastases, it appears to be an attractive
adjuvant treatment for women with breast cancer.
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